White & Case advises underwriters on Oaktree Acquisition Corp. III Life Sciences’ US$175 million IPO

Global law firm White & Case LLP has advised the underwriters on Oaktree Acquisition Corp. III Life Sciences' US$175 million initial public offering. The units, which were priced at US$10.00 each, were listed on The Nasdaq Global Market under the ticker symbol "OACCU" on October 24, 2024.

Oaktree Acquisition Corp. III Life Sciences is the third public acquisition vehicle sponsored by an affiliate of Oaktree Capital Management, L.P. and follows the successfully completed mergers between Oaktree Acquisition Corp. and Hims & Hers, a direct-to-consumer healthcare business, and between Oaktree Acquisition Corp. II and Alvotech, a global biosimilars business. The company leverages Oaktree's expertise in the life sciences sector.

The White & Case team was led by Capital Markets partner Joel Rubinstein, and associates Russell Deutsch, Christina Min and Heidi Ahmed (all in New York).

Press contact
For more information please speak to your local media contact.